SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as community excitement builds over impending EU approval for its Anktiva therapy and Saudi Arabia's expanding commitment to "all cancers" with IBRX, with many anticipating a significant short squeeze. Investors see the company as deeply undervalued, driven by its innovative immunotherapy's potential for widespread adoption in immune restoration and cancer treatment.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing significant discussion and extreme volatility after Novo Nordisk filed a patent infringement lawsuit over its compounded semaglutide products, which Hims has since ceased, with the community sharply divided between concerns over legal and regulatory risks and the belief that the stock is oversold with short-squeeze potential.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing intense scrutiny and high volatility after a clinical hold was placed on its gene therapies, RGX-111 and RGX-121, due to a patient developing a brain tumor, leading to widespread community speculation about an impending Complete Response Letter for RGX-121's imminent PDUFA decision.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl is trending after a sharp stock drop driven by a deteriorated financial outlook, unexpected leadership changes, a delayed filing, and an SEC probe into its accounting practices, leading to a community split between those seeing an oversold buying opportunity and others fearing significant financial irregularities.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending amidst divided community sentiment surrounding its recent or anticipated earnings, as investors debate whether growth in AI data center and silicon carbide can outweigh ongoing automotive sector weakness and margin pressures. The company's partnership with NVIDIA and a large share repurchase program are key discussion points fueling both bullish and bearish perspectives.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

monday.com is experiencing a sharp decline after issuing weaker-than-expected guidance and withdrawing long-term targets, intensifying market fears that AI could disrupt its traditional software business model. The community is sharply divided, with some viewing the brutal sell-off as an overreaction given the company's strong cash position and enterprise growth, while others believe AI tools pose a significant threat to the SaaS sector.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending due to strong preliminary financial results and significantly raised growth outlook, driven by robust demand for its AI data center connectivity solutions from major hyperscalers. The community is actively discussing its valuation and the ongoing relevance of its copper-based technology amidst recent market volatility.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

AMKR is gaining significant attention for its central role in advanced semiconductor packaging, which is vital for the booming AI sector and enhanced by strategic collaborations with industry leaders like Apple, Nvidia, and TSMC. The community views the company as a key beneficiary of the U.S. manufacturing reshoring trend, anticipating substantial long-term growth as it expands its domestic capabilities.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is experiencing strong bullish momentum driven by significant analyst upgrades and a new widebody aircraft order from Delta Air Lines. The community is eagerly anticipating robust upcoming earnings, with discussion focused on potential dividend increases, substantial share buybacks, and accelerating prospects in its small modular reactor (SMR) business for AI data centers and ongoing defense sector expansion.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending as strong earnings beats and raised guidance underscore its profitable growth, with the community actively discussing its strategic AI integrations, increased enterprise traction, and significant undervaluation in the evolving freelance market, further bolstered by analyst upgrades.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Issues Positive Forecast for GLSI Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Stock analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for Greenwich LifeSciences in a report released on...

Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7% - Time to Sell?

Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 6.7% - Here's Why...

Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 6.7% - Here's What Happened

Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7% - Here's What Happened...

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium PR Newswire VANCOUVER, BC, Jan...

<ul class="summary-bullets"><li>The company is running a Phase III study known as FLAMINGO-01, which is testing GLSI-100.</li><li>The approval follows the submission of manufacturing and stability data tied to multiple production runs.</li><li>More than 1,000 patients have already been screened for FLAMINGO-01.</li></ul>Greenwich LifeSciences, Inc. (GLSI) announced on Thursday that it has cleared another regulatory step in the development of its breast cancer immunotherapy as the company advances its late-stage clinical program.&nbsp;The clinical-stage biotechnology firm is running a Phase III study known as FLAMINGO-01, which is testing GLSI-100, a therapy designed to reduce the risk of cancer returning in certain breast cancer patients.<h2 class="st-heading-2">FDA Manufacturing Clearance</h2>The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial.&nbsp;Following the update,&nbsp;<a href="https://stocktwits.com/symbol/GLSI">Greenwich LifeSciences stock</a> traded over 16% higher in Thursday’s premarket. However, on Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels.&nbsp;The approval follows the submission of manufacturing and stability data tied to multiple production runs completed over the past two years.<blockquote>"With our manufacturing investments in 2023 and 2024, and now the FDA's review and approval to use the first commercial lot of finished GP2 vials in FLAMINGO-01, we have taken major steps to further de-risk the filing of a BLA in the US.”-Snehal Patel, CEO, Greenwich LifeSciences</blockquote><h2 class="st-heading-2">Trial Progress And Early Signals</h2>More than 1,000 patients have already been screened for FLAMINGO-01, with enrollment continuing at a steady pace. One treatment arm involving patients without the HLA-A*02 marker has now completed enrollment, providing a larger dataset than earlier mid-stage research.&nbsp;Preliminary observations following the initial dosing period suggest a sharp decline in recurrence rates, though the company cautioned that the findings remain early and incomplete.GLSI stock has gained over 75% higher in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-retail-chatter-up-in-a-week-what-is-driving-trader-interest/cmUzw1HR4Qo">Ondas Retail Chatter Up 131% In A Week — What's Driving Trader Interest?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did Greenwich LifeSciences Stock Soar Pre-Market Today?

The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial. 

GLSI Stock Surges Pre-Market On Clearing FDA Manufacturing Step For Its Breast Cancer Trial

Equity

The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial. 


Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,800 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 1,800 shares of the stock in a transaction dated Tuesday, January 13th. The stock was purchased at an average...

Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 2,900 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 2,900 shares of the company's stock in a transaction dated Monday, January 12th. The shares were acquired at an...

Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 2,900 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 2,900 shares of the business's stock in a transaction that occurred on Monday, January 12th. The shares were...

Greenwich LifeSciences (NASDAQ:GLSI) CEO Buys $91,848.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 4,300 shares of Greenwich LifeSciences stock in a transaction that occurred on Wednesday, December 31st. The...

Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 4,300 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 4,300 shares of the business's stock in a transaction on Wednesday, December 31st. The stock was acquired at an...

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$29.73
Prev Close	$29.00
Open	$28.20
Dividend Yield	0.00%
50-Day Moving Average	$19.35
Beta	1.32
Avg. Volume	744,757.40
PE Ratio	-19.81

52-Week High	$34.10
52-Week Low	$7.78
Market Capitalization	$401.78M
EPS (Annual)	-$1.21
Price to Book	183.09
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

GLSI
Greenwich LifeSciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GLSI News

GLSIGreenwich LifeSciences Inc